ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2644

Ultrasound to Monitor Treatment Response in Large Vessel Giant Cell Arteritis

Anne Bull Haaversen1, Viktoria Holt 2, Shagaye Nabizadeh 2, Annicken Slagsvold 2 and Andreas P Diamantopoulos 3, 1Martina Hansens Hospital, Sandvika, Norway, 2Martina Hansens Hospital, Bærum, Norway, 3Martina Hansens Hospital, SANDVIKA, Oslo, Norway

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: giant cell arteritis and diagnostic imaging, large vessel vasculitis, ultrasonography

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Giant Cell Arteritis

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: On ultrasound (US) examinations, large vessel vasculitis (LVV) has been reported to be present in up to 55% of Giant cell arteritis (GCA) patients. No consensus exists on how to evaluate treatment response in LVV. US  yields a high sensitivity and specificity on GCA diagnostics . The aim of this study was to examine if the US of the large supraaortic arteries could be used to monitor treatment response in patients with LVV-GCA.

Methods: We included retrospectively patients who were diagnosed with new-onset LVV-GCA (positive US of the supraaortic vessel(s) and typical clinical manifestations) after they had been referred to the Department of Rheumatology, Martina Hansens Hospital in Bærum, Norway between September 2017 and April 2019. The intima-media complex (IMC) thickness of the supraaortic arteries (carotid, subclavian, axillary proximal and distal) was measured at diagnosis (and within 3 days after the initiation of prednisolone) and after one month. C-reactive protein (CRP) and prednisolone dose were also registered. Appropriate statistical tests were applied and p values < 0.05 were considered as significant. Results: Twenty patients (14 females,  6 males) were included in this study, with a mean age of 67 years. The mean starting dose of prednisolone was 46 mg and one month later, prednisolone dose was reduced by 16 mg (95% CI 9-22, p< 0.005). The mean CRP at disease onset was 80 mg/dl and one month later it was reduced by 77 mg/dl (95% CI 40-115, p=0.001).  After one month, and except for the right carotid artery, a significant reduction of IMC thickness in all supraaortic vessels was observed (table 1). Conclusion: The US of the supraaortic arteries may be a useful tool to monitor treatment response in LVV-GCA. Thus, the US of the large vessels has the potential to be used for the assessment of disease activity in LVV-GCA patients. These promising results have to be confirmed in larger cohorts of patients.

Table 1. Mean differences of the IMC thickness in the supraaortic vessels


Disclosure: A. Bull Haaversen, None; V. Holt, None; S. Nabizadeh, None; A. Slagsvold, None; A. Diamantopoulos, None.

To cite this abstract in AMA style:

Bull Haaversen A, Holt V, Nabizadeh S, Slagsvold A, Diamantopoulos A. Ultrasound to Monitor Treatment Response in Large Vessel Giant Cell Arteritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/ultrasound-to-monitor-treatment-response-in-large-vessel-giant-cell-arteritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ultrasound-to-monitor-treatment-response-in-large-vessel-giant-cell-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology